(R)-2-(Ethylamino)butan-1-ol | 83890-09-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (R)-2-(Ethylamino)butan-1-ol
• 英文别名: (2R)-2-(ethylamino)butan-1-ol
• CAS: 83890-09-9
• 化学式: C₆H₁₅NO
• 分子量: 117.19
• InChiKey: BMTAVLCPOPFWKR-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS
  申请人：Hutchinson Howard John

  公开号：US20070225285A1

  公开（公告）日：2007-09-27

  Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of 5-lipoxygenase-activating protein (FLAP). Also described herein are methods of using such FLAP modulators, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions or diseases.

  本文描述了一些化合物和包含这些化合物的药物组合物，这些化合物可以调节5-脂氧合酶激活蛋白（FLAP）的活性。本文还描述了使用这些FLAP调节剂的方法，单独或与其他化合物组合使用，用于治疗呼吸系统、心血管系统和其他依赖于白三烯或介导白三烯的疾病或症状。
• Androgen Receptor Modulators
  申请人：Jernstedt Henrik

  公开号：US20080058383A1

  公开（公告）日：2008-03-06

  Treatment of Diseases caused by Disturbances of the Activity of the Androgen Receptor uses of compounds of Formula (I): (as defined herein), for the treatment of diseases caused by disturbances of the activity of androgen receptor are provided: Formula (I). Isolated compounds of Formula (I) are also provided.

  本发明提供了使用式(I)化合物（如本文所定义的）治疗由雄激素受体活性紊乱引起的疾病的方法：式(I)。本发明还提供了分离的式(I)化合物。
• 10a-Azalide Compound
  申请人：Sugimoto Tomohiro

  公开号：US20090281292A1

  公开（公告）日：2009-11-12

  [Object]: To provide a compound having a novel structure effective against Hemophilus influenzae and erythromycin resistant bacteria (for example, resistant pneumococci and streptococci) as well as against conventional erythromycin sensitive bacteria. [Solution]: A novel 10a-azalide compound represented by the formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof, or an intermediate for the preparation of the same. The compound of the present invention has superior antibacterial activity against Hemophilus influenzae , erythromycin resistant pneumococci and the like, and therefore, the compound can be used as a therapeutic agent of infectious diseases.

  【目标】提供一种具有新结构的化合物，对流感嗜血杆菌和红霉素耐药菌（例如耐药肺炎球菌和链球菌）以及传统的红霉素敏感菌具有有效作用。 【解决方案】本发明提供了一种新型10a-氮杂环十六元化合物，其化学式为（I），其药学上可接受的盐或其溶剂化物，或其制备的中间体。该化合物对流感嗜血杆菌、红霉素耐药性肺炎球菌等具有卓越的抗菌活性，因此可以作为治疗传染病的药物。
• US8097708B2
  申请人：——

  公开号：US8097708B2

  公开（公告）日：2012-01-17
• [EN] NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS<br/>[FR] NOUVEAUX PYRAZOLOPYRIMIDINES UTILISÉS COMME INHIBITEURS DES KINASES DÉPENDANTS DES CYCLINES
  申请人：SCHERING CORP

  公开号：WO2008130570A1

  公开（公告）日：2008-10-30

  [EN] In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.
  [FR] L'invention concerne, dans de nombreux modes de réalisation, une nouvelle classe de composés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs des kinases dépendants des cyclines, des méthodes de préparation de ces composés, des compositions contenant au moins un de ces composés, des méthodes de préparation de formulations pharmaceutiques comprenant au moins un de ces composés, et des méthodes utilisant ces composés ou compositions pharmaceutiques pour le traitement, la prévention, l'inhibition ou l'amélioration d'une ou de plusieurs maladies associées aux CDK.